Private label desloratadine coming
This article was originally published in The Tan Sheet
Perrigo may launch a desloratadine anti-allergy product in July 2012 or sooner under circumstances outlined in a recent Hatch-Waxman litigation settlement, the Allegan, Mich.-based private labeler announced Dec. 4. The allergy product is equivalent to Schering-Plough's Clarinex 5 mg tablets, which Wolters Kluwer estimates sold $300 million in the 12 months ending October 2008, Perrigo says. The firm says it may launch the product as a prescription or OTC product depending on its status at the time of the launch
You may also be interested in...
The first data readout for remdesivir, the much anticipated antiviral for the coronavirus pandemic, is expected in days. Scrip surveys antiviral development and regulatory experts to gauge their interest and the key aspects to watch for in the milestone announcement.
The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.